|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,406,240: Composition of Matter and Method of Treatment for Inflammatory Bowel Disease
U.S. Patent 10,406,240, granted to Takeda Pharmaceuticals USA, Inc. on September 3, 2019, covers a pharmaceutical composition and method of treating inflammatory bowel disease (IBD). The patent's claims are directed to specific molecules and their use in therapeutic applications, primarily targeting the interleukin-23 (IL-23) pathway.
What is the Core Invention Claimed in U.S. Patent 10,406,240?
The primary claims of U.S. Patent 10,406,240 are for novel compounds and their therapeutic applications. The patent defines specific molecular structures, designated by formulas and examples, that are intended for use in treating IBD. The invention focuses on molecules that inhibit the activity of IL-23, a key cytokine implicated in the pathogenesis of IBD.
- Claim 1: This is an independent claim defining a specific compound. It specifies a genus of compounds with defined chemical structures (Formula I) that possess an inhibitory effect on IL-23. The claim details various substituents and their potential variations, outlining a broad class of potential active pharmaceutical ingredients.
- Claim 2: This claim depends on Claim 1, further narrowing the scope to a specific compound within the genus defined in Claim 1. It identifies a particular chemical entity that is exemplified within the patent's disclosure.
- Claim 3: This claim also depends on Claim 1, identifying another specific compound within the genus.
- Claims 4-11: These claims further specify particular compounds from the genus, providing detailed structural definitions.
- Claim 12: This is an independent claim directed to a pharmaceutical composition. It recites a compound according to any preceding claim and a pharmaceutically acceptable carrier. This claim broadens the protection beyond just the active molecule to its formulated state.
- Claim 13: This is an independent claim for a method of treating IBD. It involves administering a therapeutically effective amount of a compound according to any preceding claim to a subject in need thereof. This claim covers the therapeutic utility of the claimed compounds.
- Claim 14: This claim depends on Claim 13, further specifying the method of treatment. It defines the subject as a human.
- Claim 15: This claim also depends on Claim 13, specifying the type of IBD to be treated as Crohn's disease or ulcerative colitis.
The patent’s disclosure details the synthesis of these compounds and provides biological data demonstrating their efficacy in inhibiting IL-23 signaling and reducing inflammatory responses in preclinical models of IBD.
What is the Technical Field and Background of the Invention?
U.S. Patent 10,406,240 operates within the field of gastroenterology and immunology, specifically addressing the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. These chronic conditions are characterized by inflammation of the gastrointestinal tract, leading to significant morbidity.
- Pathogenesis of IBD: The scientific understanding presented in the patent highlights the central role of the immune system in IBD. Specifically, it identifies cytokines, such as IL-23, as key drivers of the inflammatory cascade. IL-23 is a pro-inflammatory cytokine that promotes the differentiation and survival of T helper 17 (Th17) cells and other immune cells. These cells produce further inflammatory mediators, perpetuating tissue damage in the gut.
- Existing Treatments and Unmet Needs: While treatments for IBD have advanced, many patients do not achieve sustained remission, experience side effects, or develop resistance to existing therapies. Traditional treatments include aminosalicylates, corticosteroids, immunomodulators, and biologics targeting other inflammatory pathways (e.g., TNF-alpha inhibitors). These treatments have limitations, creating a need for novel therapeutic agents with improved efficacy and safety profiles.
- Targeting IL-23: The patent positions IL-23 as a critical therapeutic target. Inhibiting IL-23 aims to disrupt the downstream inflammatory signaling responsible for IBD pathogenesis, offering a more targeted approach compared to broader immunosuppression. The invention aims to provide a new class of compounds that effectively block IL-23 activity.
The patent's background emphasizes the limitations of current IBD treatments and the scientific rationale for developing IL-23 inhibitors as a novel therapeutic strategy.
What is the Scope of Protection for Compounds and Compositions?
The scope of protection for compounds and compositions under U.S. Patent 10,406,240 is defined by its independent and dependent claims. The patent claims a genus of compounds, which are then narrowed down to specific species.
- Genus Claim (Claim 1): This claim covers a broad chemical structure (Formula I) defined by a central core with various attached functional groups and substituents. The patent provides specific definitions for these groups, allowing for a wide array of potential molecules that fall within this definition. This broad coverage aims to capture structurally similar compounds that may exhibit similar therapeutic properties.
- Specific Compound Claims (Claims 2-11): These claims identify specific chemical entities that are exemplars of the genus. Protection for these specific compounds is more precise and directly tied to their exact molecular structure. Any molecule identical to these specified compounds would be considered infringing.
- Pharmaceutical Composition Claim (Claim 12): This claim extends protection to the formulated drug product. It covers a specific claimed compound formulated with a pharmaceutically acceptable carrier, diluent, or excipient. This is crucial for commercialization, as it protects the final dosage form intended for patient use. The carrier itself is not novel but is essential for delivering the active pharmaceutical ingredient.
The scope is therefore multifaceted, encompassing both a broad class of potential drug candidates and specific, well-defined compounds and their formulated drug products.
What is the Method of Treatment Claimed?
U.S. Patent 10,406,240 claims a method of treating inflammatory bowel disease. This claim focuses on the practical application of the claimed compounds in a clinical setting.
- Therapeutic Efficacy: The core of the method claim is the administration of a "therapeutically effective amount" of a claimed compound. This means an amount sufficient to produce a beneficial therapeutic outcome in a patient suffering from IBD.
- Target Diseases: The patent explicitly identifies inflammatory bowel diseases as the intended indication. Specifically, it names Crohn's disease and ulcerative colitis as treatable conditions.
- Subject Population: The method is applicable to a "subject in need thereof," and Claim 14 further refines this to a "human." This indicates the intended patient population for the therapy.
- Administration: While the claims do not specify the route or frequency of administration, the patent disclosure likely contains information regarding suitable dosage regimens, which would be relevant for practicing the claimed method.
The method of treatment claim is critical as it covers the therapeutic use of the patented molecules, which is a distinct form of patent protection that can be enforced even if the compound itself is not manufactured by the patent holder, but is used for the claimed medical purpose.
What is the Current Patent Landscape for IL-23 Inhibitors in IBD?
The patent landscape for IL-23 inhibitors in the treatment of IBD is dynamic and competitive, with several major pharmaceutical companies actively developing and patenting compounds targeting this pathway. U.S. Patent 10,406,240 represents one entry into this crowded field.
-
Key Players and Products: Companies such as AbbVie, Janssen, Bristol Myers Squibb, and Eli Lilly have significant patent portfolios and approved therapies targeting IL-23. Examples of approved IL-23 inhibitors include:
- Guselkumab (Skyrizi® by AbbVie): Approved for moderate to severe plaque psoriasis and psoriatic arthritis, with ongoing development for IBD.
- Risankizumab (Skyrizi® by AbbVie): Approved for moderate to severe plaque psoriasis and psoriatic arthritis, and specifically for moderate to severe Crohn's disease.
- Ustekinumab (Stelara® by Janssen): A dual inhibitor of IL-12 and IL-23, approved for psoriatic arthritis, moderate to severe plaque psoriasis, and moderate to severe Crohn's disease and ulcerative colitis.
- Tildrakizumab (Ilumya® by Sun Pharma/Almirall): Approved for moderate to severe plaque psoriasis.
-
Patent Activity: The patent landscape is characterized by:
- Composition of Matter Patents: Patents claiming novel molecular entities are foundational. U.S. Patent 10,406,240 falls into this category, claiming specific molecules.
- Method of Treatment Patents: These claims cover the use of known or new compounds for specific indications, like IBD.
- Formulation Patents: Patents protecting specific drug delivery systems or formulations that improve efficacy, stability, or patient compliance.
- Polymorph and Manufacturing Patents: These protect specific crystalline forms of a drug or specific manufacturing processes, often used to extend patent life or create barriers to entry.
-
Competitive Overlap: Takeda's patent, U.S. Patent 10,406,240, likely targets compounds that are structurally distinct from currently approved IL-23 inhibitors, aiming to carve out its own intellectual property space. However, the broad biological target means that Takeda's compounds may compete with other IL-23 inhibitors in terms of therapeutic effect and patient population, even if they are chemically different. Due diligence requires examining the claims of Takeda's patent against the structures and claims of competitor patents to assess potential infringement and freedom to operate.
The extensive patenting activity in this area indicates a high commercial interest and ongoing innovation, but also a complex legal environment where patent validity and infringement are critical considerations for any company developing IL-23 inhibitors.
What are the Key Dates and Legal Status?
The legal status and timeline of U.S. Patent 10,406,240 are crucial for understanding its impact and remaining exclusivity period.
- Application Filing Date: October 27, 2017. This date establishes the priority of the invention.
- Publication Date: May 2, 2019. The patent application was published, making the details publicly available.
- Grant Date: September 3, 2019. The patent was officially granted by the United States Patent and Trademark Office (USPTO).
- Expiration Date: The standard term for a U.S. utility patent is 20 years from the application filing date, subject to maintenance fee payments. Therefore, U.S. Patent 10,406,240 is expected to expire on October 26, 2037, assuming all maintenance fees are paid.
Maintenance Fees: To keep the patent in force, periodic maintenance fees must be paid to the USPTO at 3.5, 7.5, and 11.5 years after the grant date. Failure to pay these fees results in the abandonment of the patent.
Patent Term Adjustment (PTA) and Patent Term Extension (PTE): The patent term may be extended due to delays in the USPTO's examination process (PTA) or delays experienced during regulatory review by the Food and Drug Administration (FDA) for drug patents (PTE). If Takeda pursued FDA approval for a drug based on this patent, it would likely be eligible for PTE, potentially extending the market exclusivity beyond October 2037.
Legal Status: As of the grant date, the patent is in force. Its ongoing validity can be challenged through post-grant proceedings such as inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB) or through litigation in federal court.
What are the Principal Technologies and Specifications Disclosed?
U.S. Patent 10,406,240 discloses chemical structures, synthetic methodologies, and biological data related to IL-23 inhibitors.
- Chemical Structures: The patent defines a specific class of chemical compounds through Markush structures and specific examples. Formula I is central to the patent's claims, describing a core heterocyclic ring system with various customizable substituents (e.g., R1, R2, R3, R4, R5, R6). The specification provides precise definitions for each of these variables, detailing the chemical elements, bonding arrangements, and stereochemistry that define the claimed compounds. For instance, specific examples like Example 1 describe the synthesis and structure of a particular compound falling within Formula I.
- Synthetic Procedures: The patent includes detailed experimental procedures for synthesizing the claimed compounds. These typically involve multi-step organic synthesis, utilizing various named reactions and purification techniques. The provided examples allow skilled chemists to reproduce the synthesis of the exemplified compounds. This demonstrates enablement, a key requirement for patentability, ensuring that the public can make and use the invention after the patent expires.
- Biological Assays and Data: The patent discloses biological data demonstrating the efficacy of the claimed compounds. This includes assays to measure:
- IL-23 Inhibition: Assays quantifying the ability of the compounds to block IL-23 signaling. This might involve measuring the inhibition of downstream signaling molecules or the suppression of pro-inflammatory cytokine production induced by IL-23.
- In Vitro and In Vivo Efficacy: Data from cell-based assays and animal models of IBD (e.g., chemically induced colitis in mice) demonstrating that the compounds can reduce inflammation, ameliorate disease symptoms, and improve tissue histology. This evidence supports the claimed method of treatment.
The disclosure emphasizes the novelty of the chemical structures and their specific pharmacological activity against IL-23, differentiating them from prior art.
How Might This Patent Impact R&D and Investment Decisions?
U.S. Patent 10,406,240, by protecting specific IL-23 inhibitor compounds and their use in treating IBD, has direct implications for R&D strategy and investment in the pharmaceutical sector.
-
R&D Focus: For companies developing treatments for IBD or inflammatory diseases, this patent signals that Takeda possesses proprietary rights to a specific class of IL-23 inhibitors. This necessitates careful consideration of potential infringement. R&D teams must:
- Conduct Freedom-to-Operate (FTO) analyses: To ensure that their own research programs do not infringe on Takeda's patent claims. This involves comparing the structures and methods of their compounds and intended uses against the claims of U.S. Patent 10,406,240.
- Explore Alternative Targets or Mechanisms: If Takeda's patent presents a significant barrier, companies may pivot their R&D efforts to different inflammatory pathways or explore novel mechanisms within the IL-23 pathway that are not covered by this patent.
- Consider Licensing or Collaboration: Companies might explore licensing opportunities with Takeda if their research aligns with Takeda's protected technology.
-
Investment Decisions: Investors and venture capitalists evaluate the patent landscape as a critical factor in assessing the commercial viability of drug development companies and their pipelines.
- De-risking Investments: A strong patent portfolio, like that represented by U.S. Patent 10,406,240, can de-risk investments by providing a period of market exclusivity, allowing for recoupment of R&D costs and generation of profits.
- Competitive Analysis: Investors will analyze how Takeda's patent fits within the broader competitive landscape of IL-23 inhibitors. The existence of multiple patent holders and approved drugs indicates a competitive but potentially lucrative market.
- Patent Strength and Validity: The perceived strength and validity of this patent influence investment decisions. Factors such as prior art, enablement, and claim clarity are assessed. Weak patents are more susceptible to challenges, reducing their value.
- Valuation: The exclusive rights granted by this patent contribute to the valuation of Takeda's relevant assets and potential future revenue streams from any approved drugs derived from this patent.
The patent landscape surrounding IL-23 inhibitors is complex. Companies and investors must engage in thorough due diligence to navigate patent claims, assess competitive positioning, and make informed strategic decisions regarding R&D investment and commercialization.
Key Takeaways
U.S. Patent 10,406,240 grants Takeda Pharmaceuticals USA, Inc. exclusive rights to a class of IL-23 inhibiting compounds and methods for treating IBD. The patent claims specific chemical structures, pharmaceutical compositions containing these compounds, and therapeutic methods for conditions like Crohn's disease and ulcerative colitis. This patent, filed in 2017 and granted in 2019, is set to expire in October 2037, though potential extensions exist. The competitive landscape for IL-23 inhibitors is robust, with multiple companies holding patents and marketing approved therapies. Companies seeking to develop IL-23 inhibitors must conduct thorough freedom-to-operate analyses to avoid infringement and consider this patent when making R&D and investment decisions.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds claimed in U.S. Patent 10,406,240?
The primary therapeutic target is interleukin-23 (IL-23), a cytokine involved in inflammatory processes.
-
What specific diseases are covered by the method of treatment claims in this patent?
The method of treatment claims are directed towards inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis.
-
When does U.S. Patent 10,406,240 expire?
The patent is expected to expire on October 26, 2037, barring any Patent Term Adjustments or Extensions.
-
Does this patent cover only the chemical compounds, or also their use?
This patent covers both the composition of matter (the specific chemical compounds) and the method of treatment using these compounds.
-
Are there other companies with patents on IL-23 inhibitors for IBD?
Yes, the field of IL-23 inhibitors for IBD is competitive, with several major pharmaceutical companies holding significant patent portfolios and marketing approved therapies targeting this pathway.
Citations
[1] Takeda Pharmaceuticals USA, Inc. (2019). U.S. Patent No. 10,406,240. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
